

September 16, 2013

The Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001.
Scrip Code : 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : STAR

Dear Sirs,

Re: Updates on US FDA Inspections to our facilities

We wish to inform you that the Sterile Manufacturing Facility 2 (SFF) at Bangalore of Agila Specialties Private Limited, a wholly owned subsidiary of the Company, has received a warning letter from the United States Food and Drug Administration (US FDA).

The US FDA inspected SFF in the month of June 2013 and the inspection resulted in issuance of Form FDA 483 with observations. The Company responded to the 483 observations by implementing corrective actions.

The Company is committed to work collaboratively and expeditiously with the US FDA to resolve concerns cited in the warning letter in the shortest possible time.

Further, the Oncology facility at Bangalore of Agila Specialties Private Limited was also inspected recently by the US FDA and this facility has cleared the inspection with "Zero 483 status".

The Company has 8 US FDA approved sterile manufacturing facilities.

Thanking you.

Yours faithfully,
for **STRIDES ARCOLAB LIMITED**



BADREE KOMANDUR
CFO & COMPANY SECRETARY

